Patents by Inventor Brent Allen Reynolds

Brent Allen Reynolds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs
    Patent number: 9737589
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: August 22, 2017
    Assignee: Stemgen S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • INHIBITION OF THE TUMORIGENIC POTENTIAL OF TUMOR STEM CELLS BY LIF AND BMPS
    Publication number: 20160228511
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Application
    Filed: November 16, 2015
    Publication date: August 11, 2016
    Applicant: STEMGEN S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
    Patent number: 9220756
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: December 29, 2015
    Assignee: STEMGEN S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • INHIBITION OF THE TUMORIGENIC POTENTIAL OF TUMOR STEM CELLS BY LIF AND BMPS
    Publication number: 20100167999
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Application
    Filed: July 19, 2006
    Publication date: July 1, 2010
    Applicant: Stemgen S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds